Gene Therapy on Neurological Diseases Market to Reach USD 15.40 Billion by 2034, Driven by Advances in Precision Medicine - SRI

London, UK - June 2026 | Strategic Revenue Insights Inc. – The Gene Therapy On Neurological Diseases Market encompasses therapeutic interventions that target the underlying genetic causes of neurological disorders including Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, Spinal Muscular Atrophy, ALS, and Epilepsy. Unlike conventional treatments that provide only symptomatic relief, gene therapy approaches offer the potential for disease modification or cure by correcting defective genetic sequences. Rapid advances in CRISPR gene editing, viral vector delivery systems, and genomic sequencing are collectively elevating this market into one of the most dynamic segments within advanced healthcare globally.

A comprehensive assessment of this rapidly evolving market can be accessed through Strategic Revenue Insights at the link below, focused on Gene Therapy On Neurological Diseases:

https://www.strategicrevenueinsights.com/industry/gene-therapy-on-neurological-diseases-market

The increasing global burden of neurodegenerative diseases is the foundational demand driver for this market. As populations age worldwide, the incidence of Alzheimer's Disease, Parkinson's Disease, and related neurological conditions is rising at an accelerating pace. This creates an expanding patient population for whom conventional pharmacological approaches offer limited efficacy, positioning gene therapy as a clinically compelling and commercially significant treatment alternative with strong long-term demand fundamentals.

Breakthrough innovations in gene editing and delivery technology are directly enabling faster and more effective therapy development. CRISPR-Cas9 gene editing tools allow precise modification of disease-causing genetic sequences with unprecedented accuracy. Advancements in adeno-associated virus vector platforms, championed by companies including Voyager Therapeutics and REGENXBIO, are improving the targeted delivery of therapeutic genes to central nervous system cells. These technological improvements are enhancing both the safety profile and therapeutic efficacy of gene therapy treatments across neurological indications.

Browse the associated report:

https://www.strategicrevenueinsights.com/pt/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/fr/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/it/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/da/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/es/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/kr/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/ja/industry/gene-therapy-on-neurological-diseases-market

https://www.strategicrevenueinsights.com/pt/industry/gene-therapy-on-neurological-diseases-market

Growing investment in genomic sequencing and bioinformatics is enabling the identification of specific genetic mutations responsible for individual neurological disease cases. This capability underpins the development of personalized gene therapies tailored to patient-specific genetic profiles. Pharmaceutical companies, government research agencies, and academic institutions are substantially increasing research and development funding directed at neurological gene therapy. Strategic collaborations between biotechnology firms and research institutes are accelerating the clinical pipeline and shortening the path from discovery to commercialization.

The market is segmented by disease type into Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Spinal Muscular Atrophy, Epilepsy, Alzheimer's Disease, and others. Spinal Muscular Atrophy is a landmark segment, highlighted by Novartis's Zolgensma, which demonstrated the commercial viability of gene therapy for neurological conditions. Parkinson's Disease and Alzheimer's Disease represent the largest long-term opportunity segments given their high global prevalence. Huntington's Disease and ALS are attracting intensive research investment due to their clear genetic causation and the availability of orphan drug regulatory pathways that accelerate approval timelines.

The market is segmented by route of administration into intrathecal, intracerebral, intravenous, intraventricular, and other delivery methods. Intrathecal administration is a leading segment due to its ability to deliver therapeutic genes directly to the central nervous system with high precision and minimized systemic exposure. Intracerebral administration is particularly suited to focal neurological conditions affecting specific brain regions. Intravenous administration is growing as a preferred route for systemic gene delivery applications due to its non-invasive nature and relative ease of clinical implementation across diverse patient populations.

In vivo gene therapy is the dominant therapy type segment, involving direct delivery of therapeutic genetic material into the patient's body using optimized viral vector systems. This approach benefits from greater scalability and clinical practicality. Ex vivo gene therapy, which involves modifying patient-derived cells outside the body before reinfusion, offers superior precision and reduced risk of off-target effects. Both modalities are advancing through clinical development pipelines, with in vivo approaches currently representing a larger share of active clinical trials and approved commercial products within neurological disease indications.

Get a Free Sample Copy of this Report and you can Buy Now Directly @

https://www.strategicrevenueinsights.com/checkout/gene-therapy-on-neurological-diseases-market?license=multi

Hospitals represent the largest end-user segment, serving as the primary clinical setting for gene therapy administration and patient management. Specialty neurology clinics are a significant and growing segment, delivering focused neurological care and increasingly offering access to advanced therapy programs. Research institutes and gene therapy centers play a critical role in advancing the clinical pipeline through sponsored trials and translational research. These specialized end-user environments are expanding in number and capability as gene therapy transitions from experimental to standard-of-care status in select neurological indications.

The high cost of gene therapy development and commercial treatment delivery remains the most significant barrier to broader market penetration. Complex manufacturing processes, stringent regulatory requirements, and extensive clinical trial obligations contribute to treatment costs that currently limit patient access in many healthcare systems.

Regulatory approval timelines pose additional challenges, as gene therapy products require comprehensive safety and efficacy demonstration before commercialization. Immune reactions associated with viral vector delivery systems represent an ongoing clinical safety concern requiring careful patient screening and monitoring. The absence of standardized reimbursement frameworks across many markets further restricts adoption, necessitating health economics advocacy alongside clinical evidence generation.

Related Report:

Nutritional and Dietary Supplement Market

https://www.strategicrevenueinsights.com/industry/nutritional-and-dietary-supplement-market

Mobile Phone Accessories Market

https://www.strategicrevenueinsights.com/industry/mobile-phone-accessories-market

Video Streaming Market

https://www.strategicrevenueinsights.com/industry/video-streaming-market

Spray Guided GDI Fuel Rail Market

https://www.strategicrevenueinsights.com/industry/spray-guided-gdi-fuel-rail-market

Smart Vents and Airflow Control Systems Market

https://www.strategicrevenueinsights.com/industry/smart-vents-and-airflow-control-systems-market

United States: The U.S. leads the global market with an estimated size of $3.5 billion and a CAGR of 14%. Strong R&D investment, favorable regulatory frameworks, and the concentration of leading biotechnology companies drive this dominance.

Japan: Japan is among the fastest-growing markets at a CAGR of 15%, valued at approximately $1 billion. A rapidly aging population and government support for advanced therapy development are key growth accelerators.

Germany: Germany's market, valued at around $1.2 billion with a CAGR of 12%, benefits from strong research infrastructure and government funding for rare disease innovation.

United Kingdom: The U.K. market, valued at approximately $800 million with a CAGR of 13%, is supported by leading academic institutions and established biotechnology research clusters.

China: China is emerging rapidly at a CAGR of 16%, valued at approximately $700 million, driven by large patient populations, growing healthcare investment, and targeted government support for biotechnology advancement.

Novartis leads the market with its commercially approved Zolgensma therapy for Spinal Muscular Atrophy. Roche and Biogen are major players advancing gene therapy pipelines for Alzheimer's and Parkinson's Disease. Sarepta Therapeutics and Voyager Therapeutics are prominent innovators in rare neurological disorder gene therapies. uniQure is a pioneer in Huntington's Disease gene therapy development. PTC Therapeutics, AskBio, MeiraGTx, REGENXBIO, Taysha Gene Therapies, Neurogene, Lysogene, and Prevail Therapeutics collectively define a dynamic and rapidly evolving competitive landscape.

The Gene Therapy On Neurological Diseases Market is positioned for exceptional growth through 2034, driven by maturing gene editing platforms, expanding clinical pipelines, and increasing regulatory experience with advanced therapy approvals. Companies that invest in scalable manufacturing, cost reduction strategies, and robust reimbursement frameworks will lead commercialization in this transformative and high-impact segment of modern medicine.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., a distinguished subsidiary of SRI Consulting Group Ltd, stands as a premier provider of data-driven market intelligence, empowering organizations globally to navigate complex business landscapes with confidence and precision. Headquartered in London, United Kingdom, our firm specializes in delivering comprehensive syndicated research reports, bespoke consulting solutions, and actionable strategic insights that enable clients to make informed, forward-thinking decisions in an increasingly competitive marketplace.

Our dedicated team of accomplished analysts, strategically positioned in London with an extensive global network, maintains continuous vigilance over evolving market dynamics, identifying emerging trends and uncovering high-potential growth opportunities that drive sustained client success. As an integral component of SRI Consulting Group Ltd, we uphold unwavering commitments to analytical accuracy, clarity of presentation, and practical applicability, assisting organizations in navigating competitive terrain, optimizing strategic initiatives, and accelerating revenue trajectories.

Through the integration of rigorous research methodologies with profound industry expertise, Strategic Revenue Insights Inc. delivers comprehensive market perspectives that generate measurable outcomes and establish enduring competitive advantages for our clients across diverse sectors and geographies.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44 7877403352

Address: Suite 10, Capital House, 61 Amhurst Road, E8 1LL

City: London

State: London

Country: United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

For partnership inquiries, custom research requests, or detailed market analysis consultations, we invite you to connect with our team of experts who are committed to delivering strategic intelligence that transforms business outcomes.